EX-99.1 2 icu-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates Business highlights include: • Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled • Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) • Positive survival results reported from QUELIMMUNE SAVE Surveillance Registry • Webcast call today at 4:30 p.m. Eastern Time DENVER, CO (August 13, 2025) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today financial results for the three months ended June 30, 2025, and provided business updates on key initiatives. “Since the beginning of the second quarter, we have made great progress on several fronts,” said Eric Schlorff, CEO of SeaStar Medical. “We enrolled 31 additional patients in the NEUTRALIZE-AKI trial, reported three new QUELIMMUNE customers from top-rated U.S.-based children’s hospitals, announced positive survival results for the…
Open exhibit ↗Current Report · Items 2.01, 9.01 · 8-K
SeaStar Medical Holding Corporation
ICUNASDAQEQUITYCurrent
Completion of Acquisition or Disposition of Assets
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description No. ──────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release dated August 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Company context
We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device (“SCD”) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases.